SELLAS Life Sciences Group, Inc. (SLS) · Nov 20, 2026 · Share issuance
$150M equity raise — 11.54M shares at $13.00; $150.0M gross proceeds
SELLAS prices a $150M stock offering after its Phase 3 win, strengthening funding for FDA preparation and SLS009 while diluting existing holders.
SELLAS is a late-stage oncology biotech moving from a positive Phase 3 GPS result toward FDA preparation and potential commercialization, while continuing to develop SLS009 in AML. The raise materially strengthens that transition. SELLAS will receive $150.0 million in gross proceeds before fees from selling 11,538,462 shares at $13.00, with a further 1,730,769-share underwriter option. That gives the company fresh capital for regulatory work, launch preparation and SLS009 development rather than forcing an immediate follow-on financing after its cash balance was already $134.7 million at September 30.
The trade-off is straightforward dilution, not a change in clinical evidence. The offering was already announced, so the pricing and size are the new information; the underlying financing decision was largely known. The new shares represent roughly 5.7% of the previously outstanding share count, before any exercise of the additional-share option, while the $13 price fixes the capital cost for existing holders. 〔0〕
Bottom line: This is a modestly constructive funding event for a company entering the regulatory and commercialization phase, but it advances the story by issuing equity rather than by adding new clinical proof. The financing was partly expected, making the main change better funding visibility—not a rewritten investment case.
SLS009 preliminary topline data, Q4 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!